Allopurinol Therapy in Patients with Chronic Kidney Disease

Introduction to Allopurinol Therapy

• The American College of Rheumatology strongly recommends allopurinol as the preferred first-line urate-lowering therapy even in patients with moderate-to-severe CKD (stage ≥3), including those with stage 4 CKD, due to its efficacy, tolerability, safety, and lower cost compared to alternatives 1, 3

Initial Dosing and Titration

• Start allopurinol at 50 mg daily in patients with eGFR 24 mL/min (CKD stage 4), then titrate upward by 50-100 mg every 2-5 weeks to achieve a serum uric acid target below 6 mg/dL, with careful monitoring for hypersensitivity reactions 1, 2
• Increase the dose by 50-100 mg increments every 2-5 weeks until serum uric acid falls below 6 mg/dL, as recommended by the American College of Rheumatology and supported by evidence from Annals of the Rheumatic Diseases 1, 4

Dose Adjustment and Monitoring

• Despite traditional teaching, doses can be increased above 300 mg daily even with renal impairment if needed to reach target, provided there is adequate monitoring for toxicity, as suggested by the American College of Rheumatology 1, 2
• Monitor serum uric acid levels every 2-4 weeks during titration to guide dose adjustments, and consider monitoring liver function tests during early therapy given the hepatitis risk with allopurinol hypersensitivity syndrome 2

Gout Flare Prophylaxis

• Initiate prophylactic colchicine when starting allopurinol to prevent mobilization flares, but reduce the dose due to renal impairment, with standard colchicine prophylaxis being 0.6 mg daily, but in severe renal impairment (eGFR <30), consider 0.3 mg daily or 0.6 mg every other day 2

Alternative Therapies

• If the maximum tolerated dose of allopurinol fails to achieve serum uric acid <6 mg/dL, consider switching to febuxostat, which requires no dose adjustment in renal impairment, as recommended by Praxis Medical Insights 2, 5
• Febuxostat can be used at standard doses (40-80 mg daily) regardless of CKD stage and has demonstrated superior efficacy compared to renally-adjusted allopurinol in CKD patients, but carries an FDA black box warning for cardiovascular risk 5